Semaglutide

The Uncomfortable Truth About Ozempic

Kurzgesagt – In a Nutshell

GLP-1 receptor agonist used for diabetes and obesity; long-acting variants lead to sustained appetite suppression; approved 2005 (diabetes) and 2014 (obesity).

378 ‒ Women’s health & performance: how training, nutrition, & hormones interact across life stages

Peter Attia MD

Dr. Mehmet Oz on Fixing American Healthcare + Fraud | Live from Davos

All-In Podcast

Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver

Andrew Huberman

A GLP-1 agonist, known by brand names like Ozempic, used for type 2 diabetes and observed to cause weight loss.

252 ‒ Latest insights on Alzheimer’s disease, cancer, exercise, nutrition, and fasting

Peter Attia MD

A GLP-1 agonist, mentioned as a drug for weight loss, with concerns about its use for minor weight loss and potential for muscle wasting if protein intake is not maintained.

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

A GLP-1 drug approved for diabetes in 2017 (Ozempic) and weight loss (Wegovy), with a half-life of 7 days, leading to about 16% weight loss in trials.

Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]

Peter Attia MD

A GLP-1 agonist drug discussed for type 2 diabetes and obesity treatment, known by brand names Ozempic and Wegovy.

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A GLP-1 receptor agonist available in injectable (oral formulation outcome data ongoing) form, approved for type 2 diabetes with cardiovascular outcome data, and a separate weight loss indication for obesity/overweight with risk factors.